RESEARCH MONOGRAPH · KDC-MN-381

Methamphetamine (Research)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

69/100

Higher CNS penetration than amphetamine; clinically prescribed but the neurotoxicity story is real

Methamphetamine is amphetamine with an N-methyl group, and that one methyl changes the pharmacology in important ways. Higher lipophilicity, faster blood-brain barrier crossing, more potent at the dopamine transporter relative to NET, and a longer plasma half-life (10 to 12 hours versus 8 to 10 for amphetamine). All of which makes it more potent per milligram and more reinforcing.

Yes, it's also a prescribed medication. Desoxyn, d-methamphetamine HCl, FDA-approved for ADHD and short-term obesity since 1944. Niche use, vastly outpaced by amphetamine and methylphenidate prescribing, but it exists. The clinical efficacy in ADHD is real and matches d-amphetamine in head-to-head work. So the question of whether the molecule itself is uniquely dangerous versus how it's typically used (high-dose, smoked, IV) is genuinely a separable question.

The research literature splits cleanly. Therapeutic-dose chronic methamphetamine in animal models shows monoamine adaptations but not the dramatic dopamine terminal pruning you see at high-dose binge exposures. The Volkow PET work in human meth users shows DAT density reductions that partially recover with abstinence. So the neurotoxicity is real but heavily dose- and pattern-dependent.

What we like for research use is what we like about most stimulants: clean pharmacology, well-characterized binding profile, and a useful tool for probing high-affinity DAT pharmacology with deeper CNS partitioning than amphetamine.

What we don't like is honestly the regulatory and reputational baggage. Almost no university wants to run a methamphetamine study even with proper licensing because the optics are bad and the IRB friction is high. So the human research literature has stagnated compared to what it could be.

Sourcing is heavily regulated, Schedule II in the US, equivalent everywhere else, reference-grade material is available through licensed channels for forensic and pharmaceutical analytical work. Purity and enantiomeric integrity are the critical QC parameters; the d-isomer is the prescribed pharmacologically active form, l-methamphetamine is a much weaker compound used in some OTC nasal decongestants.

Staying power is mechanism-driven; whatever happens to public health policy, the molecule remains the high-affinity reference for DAT releaser studies.

Evidence: 82
Mechanism: 92
Reliability: 85
Safety: 40
Sourcing: 45
Value: 55
Signal: 80
Staying power: 75

Plain-language summary Intrigue 60 / 100

Methamphetamine is the N-methylated cousin of amphetamine. The extra methyl group makes it more lipophilic and substantially better at crossing into the brain, so d-methamphetamine releases central dopamine roughly five times more potently than d-amphetamine on a per-milligram basis. It actually has FDA approval as Desoxyn (1944) for ADHD and obesity, though prescriptions are vanishingly rare; the public knows it primarily as the illicit Schedule II drug. Same mechanism as amphetamine: reverses the monoamine transporters to force release rather than blocking reuptake. The l-enantiomer is the active component of Vicks Vapor Inhaler, which is a strange historical footnote. Used in research as a high-potency reference monoamine releaser. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

N-methylated phenethylamine stimulant

The N-methylated analog of amphetamine; FDA-approved (Desoxyn) for ADHD and obesity but principally encountered as an illicit drug; a research-grade pharmacology probe.

Abstract

Methamphetamine (N-methyl-1-phenylpropan-2-amine; CAS 537-46-2; molecular formula C10H15N; molecular weight 149.23) is the N-methylated analog of amphetamine, approved by the FDA in 1944 (Desoxyn) for narcolepsy, ADHD, and obesity. Mechanism is the same as amphetamine (monoamine release via reverse transport) with greater CNS penetration owing to the increased lipophilicity from N-methylation. The d-enantiomer (d-methamphetamine) is approximately 5-fold more potent than d-amphetamine at central dopamine release; the l-enantiomer (l-methamphetamine) is the active component of Vicks Vapor Inhaler. Plasma half-life is approximately 9 to 12 hours. Schedule II prescription drug; principally encountered as illicit Schedule II. Used as a research-grade reference compound for monoamine release pharmacology and as a clinical (rare) ADHD medication.

Mechanism of action

N-methylated amphetamine; same monoamine releaser mechanism with increased CNS penetration and ~5-fold greater dopamine release potency than d-amphetamine.

Reported research dose ranges

Clinical (Desoxyn) 5 to 25 mg in the published literature.

References

Cruickshank CC, Dyer KR. A review of the clinical pharmacology of methamphetamine. Addiction 2009.
Krasnova IN, Cadet JL. Methamphetamine toxicity and messengers of death. Brain Res Rev 2009.
Heal DJ, et al. Amphetamine, past and present. J Psychopharmacol 2013.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-381

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Methamphetamine (Research)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs